IMMUNOVANT, INC. (IMVT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $20.00K; Additional Paid in CapitalUSD $2.63B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $725.00K; Retained Earnings (Accumulated Deficit)USD $-1.90B.
- 2026-03-31: Common Stock, Value, IssuedUSD $20.00K; Additional Paid in CapitalUSD $2.60B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $730.00K; Retained Earnings (Accumulated Deficit)USD $-1.75B.
- 2025-12-31: Common Stock, Value, IssuedUSD $20.00K; Additional Paid in CapitalUSD $2.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.20M; Retained Earnings (Accumulated Deficit)USD $-1.60B.
- 2025-09-30: Common Stock, Value, IssuedUSD $17.00K; Additional Paid in CapitalUSD $2.00B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.45M; Retained Earnings (Accumulated Deficit)USD $-1.49B.
IMMUNOVANT, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Outstanding USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.00K | $2.63B | $725.00K | $-1.90B | $735.39M | 3 month · $13.53M | (m) |
| 2026-03-31 | $20.00K | $2.60B | $730.00K | $-1.75B | $852.59M | 12 month · $54.89M | (m) |
| 2025-12-31 | $20.00K | $2.58B | $1.20M | $-1.60B | $986.13M | 3 month · $12.53M | (m) |
| 2025-09-30 | $17.00K | $2.00B | $1.45M | $-1.49B | $519.71M | 3 month · $13.19M | (m) |
| 2025-06-30 | $16.00K | $1.97B | $1.74M | $-1.36B | $608.54M | 3 month · $18.39M | (m) |
| 2025-03-31 | $16.00K | $1.95B | $1.46M | $-1.24B | $707.45M | 12 month · $49.46M | (m) |
| 2024-12-31 | $14.00K | $1.48B | $2.48M | $-1.13B | $352.62M | 3 month · $11.65M | (m) |
| 2024-09-30 | $14.00K | $1.47B | $1.91M | $-1.02B | $449.05M | 3 month · $12.69M | (m) |
| 2024-06-30 | $14.00K | $1.46B | $1.82M | $-912.83M | $544.66M | 3 month · $13.44M | (m) |
| 2024-03-31 | $14.00K | $1.44B | $1.91M | $-825.68M | $617.76M | 12 month · $41.01M | (m) |
| 2023-12-31 | $14.00K | $1.43B | $-600.00K | $-750.36M | $679.34M | 3 month · $10.20M | (m) |
| 2023-09-30 | $13.00K | $950.23M | $513.00K | $-698.95M | $251.81M | 3 month · $10.50M | (m) |
| 2023-06-30 | $13.00K | $939.55M | $582.00K | $-640.28M | $299.87M | 3 month · $10.65M | (m) |
| 2023-03-31 | $13.00K | $927.98M | $852.00K | $-566.35M | $362.49M | 12 month · $31.97M | (m) |
| 2022-12-31 | $13.00K | $920.20M | $1.38M | $-506.92M | $414.68M | 3 month · $8.86M | (m) |
| 2022-09-30 | $12.00K | $840.66M | $-1.24M | $-443.69M | $395.75M | 3 month · $8.05M | (m) |
| 2022-06-30 | $12.00K | $832.50M | $-263.00K | $-395.76M | $436.49M | 3 month · $7.55M | $0.00 |
| 2022-03-31 | $12.00K | $824.80M | $404.00K | $-355.39M | $469.82M | 12 month · $33.14M | $0.00 |
| 2021-12-31 | $12.00K | $812.93M | $419.00K | $-308.22M | $505.15M | 3 month · $9.95M | $0.00 |
| 2021-09-30 | $12.00K | $802.77M | $442.00K | $-266.83M | $536.40M | 3 month · $7.67M | $0.00 |
| 2021-06-30 | $10.00K | $594.38M | $273.00K | $-229.13M | $365.53M | 3 month · $3.82M | $0.00 |
| 2021-03-31 | $10.00K | $590.42M | $-298.00K | $-198.66M | $391.48M | 12 month · $18.64M | $0.00 |
| 2020-12-31 | $10.00K | $584.17M | $467.00K | $-170.50M | $414.15M | 3 month · $5.99M | $0.00 |
| 2020-09-30 | $10.00K | $577.34M | $-222.00K | $-138.72M | $438.41M | 3 month · $3.31M | $0.00 |
| 2020-06-30 | $8.00K | $385.69M | $10.00K | $-117.93M | $267.77M | 3 month · $3.92M | $0.00 |
| 2020-03-31 | $5.00K | $185.31M | $-16.00K | $-91.23M | $94.07M | 12 month · $6.79M | $0.00 |
| 2019-12-31 | $5.00K | $182.68M | $-147.00K | $-70.67M | $111.86M | 3 month · $1.33M | (m) |
| 2019-09-30 | $353.00 | $4.69M | (m) | $306.94K | $-23.28M | 3 month · $3.12M | (m) |
| 2019-06-30 | $355.00 | $4.82M | (m) | $181.85K | $-12.11M | 3 month · $537.00K | (m) |
| 2019-03-31 | $4.00K | $31.83M | $346.00K | $-24.84M | $7.34M | 9 month · $31.00K | (m) |
| 2018-12-31 | $288.00 | $24.71K | (m) | $-448.00 | $7.96M | 3 month · $12.00K | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | $2.32M | 3 month · $1.00K | (m) |
| 2018-07-06 | (m) | (m) | (m) | (m) | $-411.00K | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-411.00K | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-1.50M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |